Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer

摘要: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in Western countries. Despite progress achieved with introduction new cytotoxic agents, CRC recurrence rates for patients resected stage II and/or III disease remain higher than 20%. Furthermore, diagnosed metastatic CRC, median survival time remains below 2 years and cure often an elusive goal. These data highlight need more-effective systemic therapies. The EGFR frequently overexpressed has been associated malignant phenotype. Numerous clinical trials are now investigating role EGFR-targeted agents have produced some encouraging results. Panitumumab a fully human IgG(2) monoclonal antibody that randomized phase trial was shown to increase efficacy when added best supportive care chemotherapy-refractory CRC. In I-III trials, panitumumab safe well tolerated, most its adverse effects related form skin toxic effect. Early studies assessing safety alongside chemotherapy also yielded promising results, this combination being investigated first-line second-line settings trials.